Bordetella pertussis PT and FHA ELISAs
Two innovative new ELISA systems provide separate detection of the diagnostically relevant antibodies in Bordetella pertussis infections: antibodies against pertussis toxin (PT) and antibodies against filamentous haemagglutinin (FHA). Independent determination of these antibodies is critical to enable a meaningful diagnostic interpretation, as emphasised in recent publications. Determination of IgG antibodies against PT is a front-line test for the serological diagnosis of pertussis infections; it is in many cases sufficient to perform a single determination of anti-PT IgG antibodies to detect an acute infection. Results of over 100 IU/mL provide a clear indication of a fresh infection or recent vaccination, and the second blood withdrawal can be omitted. If the titre is under 40 IU/mL no further tests are required unless clinical symptoms are suggestive of a pertussis infection. Only unclear results in the range 40 to 100 IU/mL need to be followed up with a second sample taken 7-10 days later. For a more in depth investigation, IgA antibodies against PT and IgG or IgA antibodies against FHA are measured separately. Age-dependent reference ranges are available on the internet.
The Anti-Bordetella pertussis Toxin ELISA (IgA or IgG) and the Anti-Bordetella FHA ELISA (IgA or IgG) correspond to current guidelines from European reference centres. Results are evaluated in international units (IU/mL) – a worldwide first for the detection of FHA antibodies. All processes, including incubation, evaluation and result archiving, can be fully automated. A supplementary product for Bordetella serodiagnostics, the immunoblot EUROLINE Bordetella pertussis (IgA or IgG), provides separate, parallel investigation of antibodies against adenylate cyclase toxin (ACT), PT and FHA and can also be fully automated using specially developed devices and software.
Supplier: EUROIMMUN AG
Website:
